China Universal Asset Management »

Enliven Therapeutics shares owned by China Universal Asset Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by China Universal Asset Management from 13F filings

Historical chart of China Universal Asset Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by China Universal Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by China Universal Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $140k 8.0k 17.61
2023-12-31 $66k 4.8k 13.86

More positions owned by China Universal Asset Management

Microsoft Corp Common Stock (MSFT)
Nvidia Corp Common Stock (NVDA)
Amazon.com Common Stock (AMZN)
Meta Platforms Inc-class A Common Stock (META)
Vertex Pharmaceuticals Common Stock (VRTX)
Amgen Common Stock (AMGN)
Servicenow Common Stock (NOW)
Gilead Sciences Common Stock (GILD)
Regeneron Pharmaceuticals Common Stock (REGN)
Alphabet Inc-cl A Common Stock (GOOGL)
Adobe Common Stock (ADBE)
Broadcom Common Stock (AVGO)
Visa Inc-class A Shares Common Stock (V)
Apple Common Stock (AAPL)
Uber Technologies Common Stock (UBER)

View all positions for China Universal Asset Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
5AM Venture Management
VR Adviser
Commodore Capital
Citadel Advisors
Fairmount Funds Management
RA Capital Management
Vanguard Group
Boxer Capital
Henderson Group
Logos Global Management
Charles Schwab Investment Management
Bank of New York Mellon
BML Capital Management
Barclays

View all funds holding Enliven Therapeutics